Cytoplasmic localization of â-catenin is a marker of poor outcome in breast cancer patients

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 1, 2010, Pages 301-309

  López Knowles, Elena ^a   Zardawi, Sarah J ^a   McNeil, Catriona M ^a,c,d   Millar, Ewan K A ^a,e,f,g   Crea, Paul ^h   Musgrove, Elizabeth A ^a,g   Sutherland, Robert L ^a,g   O'Toole, Sandra A ^a,b,g,i  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b University of Sydney   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ST GEORGE HOSPITAL   (Australia)

^f UNIVERSITY OF WESTERN SYDNEY   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; TAMOXIFEN; ESTROGEN RECEPTOR; PIK3CA PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVERSE OUTCOME; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SCORING SYSTEM; UNIVARIATE ANALYSIS; BIOSYNTHESIS; BREAST TUMOR; CELL MEMBRANE; CHEMISTRY; FEMALE; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PHYSIOLOGY; PROTO ONCOGENE; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TREATMENT OUTCOME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BETA CATENIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL MEMBRANE; CYTOPLASM; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 74549167752     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0741     Document Type: Article

References (39)

1. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
2. Candidus S, Bischoff P, Becker KF, Hofler H. No evidence for mutations in the α- and β-catenin genes in human gastric and breast carcinomas. Cancer Res 1996;56:49-52.
3. Jamora C, Fuchs E. Intercellular adhesion, signalling and the cytoskeleton. Nat Cell Biol 2002;4:E101-8.
4. Bek S, Kemler R. Protein kinase CKII regulates the interaction of β-catenin with α-catenin and its protein stability. J Cell Sci 2002;115: 4743-53.
5. Nelson WJ, Nusse R. Convergence of Wnt, β-catenin, and cadherin pathways. Science (New York, NY) 2004;303:1483-7.
6. Rubinfeld B, Albert I, Porfiri E, et al. Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly. Science (New York, NY) 1996;272:1023-6.
7. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16:3797-804.
8. Hatsell S, Rowlands T, Hiremath M, Cowin P. β-Catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia 2003;8:145-58.
9. Millar EK, Dean JL, McNeil CM, et al. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene 2009;28:1812-20.
10. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
11. Lopez-Knowles E, O'Toole SA, McNeil CM, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2009.
12. Zardawi SJ, Zardawi I, McNeil C, et al. High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathol. In press.
13. Olmeda D, Castel S, Vilaro S, Cano A. β-Catenin regulation during the cell cycle: implications in G2/M and apoptosis. Mol Biol Cell 2003;14:2844-60.
14. Hayward P, Balayo T, Martinez Arias A. Notch synergizes with axin to regulate the activity of armadillo in Drosophila. Dev Dyn 2006;235: 2656-66.
15. Alves-Guerra MC, Ronchini C, Capobianco AJ. Mastermind-like 1 is a specific coactivator of β-catenin transcription activation and is essential for colon carcinoma cell survival. Cancer Res 2007;67:8690-8.
16. Espinosa L, Ingles-Esteve J, Aguilera C, Bigas A. Phosphorylation by glycogen synthase kinase-3 β down-regulates Notch activity, a link for Notch and Wnt pathways. J Biol Chem 2003;278:32227-35.
17. Rodilla V, Villanueva A, Obrador-Hevia A, et al. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci U S A 2009;106:6315-20.
18. Cheang MC, van de Rijn M, Nielsen TO. Gene expression profiling of breast cancer. Annu Rev Pathol 2008;3:67-97.
19. Wong SC, Lo ES, Lee KC, Chan JK, Hsiao WL. Prognostic and diagnostic significance of β-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res 2004;10:1401-8.
20. Lin SY, Xia W, Wang JC, et al. β-Catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 2000;97:4262-6.
21. Prasad CP, Gupta SD, Rath G, Ralhan R. Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between β-catenin, dishevelled and cyclin D1 expression. Oncology 2007; 73:112-7.
22. Dolled-Filhart M, McCabe A, Giltnane J, et al. Quantitative in situ analysis of β-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 2006;66: 5487-94.
23. Fanelli MA, Montt-Guevara M, Diblasi AM, et al. P-cadherin and β-catenin are useful prognostic markers in breast cancer patients; β-catenin interacts with heat shock protein Hsp27. Cell Stress Chaperones 2008;13:207-20.
24. Bankfalvi A, Terpe HJ, Breukelmann D, et al. Immunophenotypic and prognostic analysis of E-cadherin and β-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopathology 1999;34:25-34.
25. Chung GG, Zerkowski MP, Ocal IT, et al. β-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer 2004;100: 2084-92.
26. Dillon DA, D'Aquila T, Reynolds AB, Fearon ER, Rimm DL. The expression of p120ctn protein in breast cancer is independent of α- and β-catenin and E-cadherin. Am J Pathol 1998;152:75-82.
27. Nakopoulou L, Gakiopoulou H, Keramopoulos A, et al. c-met tyrosine kinase receptor expression is associated with abnormal β-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology 2000;36:313-25.
28. Karayiannakis AJ, Nakopoulou L, Gakiopoulou H, et al. Expression patterns of β-catenin in in situ and invasive breast cancer. Eur J Surg Oncol 2001;27:31-6.
29. Krieghoff E, Behrens J, Mayr B. Nucleo-cytoplasmic distribution of β-catenin is regulated by retention. J Cell Sci 2006;119:1453-63.
30. Neufeld KL, Zhang F, Cullen BR, White RL. APC-mediated downregulation of β-catenin activity involves nuclear sequestration and nuclear export. EMBO Rep 2000;1:519-23.
31. Shimura T, Takenaka Y, Tsutsumi S, et al. Galectin-3, a novel binding partner of β-catenin. Cancer Res 2004;64:6363-7.
32. Ozaki S, Ikeda S, Ishizaki Y, et al. Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol Rep 2005;14:1437-43.
33. Jin Z, Tamura G, Tsuchiya T, et al. Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer 2001;85:69-73.
34. Prasad CP, Mirza S, Sharma G, et al. Epigenetic alterations of CDH1 and APC genes: relationship with activation of Wnt/β-catenin pathway in invasive ductal carcinoma of breast. Life Sci 2008;83: 318-25.
35. Schlosshauer PW, Brown SA, Eisinger K, et al. APC truncation and increased β-catenin levels in a human breast cancer cell line. Carcinogenesis 2000;21:1453-6.
36. Wong SC, Lo SF, Lee KC, et al. Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. J Pathol 2002;196:145-53.
37. Korkaya H, Paulson A, Charafe-Jauffret E, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/β-catenin signaling. PLoS Biol 2009;7:e1000121.
38. Fuchs SY, Ougolkov AV, Spiegelman VS, Minamoto T. Oncogenic β-catenin signaling networks in colorectal cancer. Cell Cycle 2005;4: 1522-39.
39. Hiscox S, Jiang WG, Obermeier K, et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation. Int J Cancer 2006;118:290-301.